ImmunoCellular appoints Andrew Gengos as chief executive
pharmafile | December 5, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Gengos, ImmunoCellular
Clinical stage firm ImmunoCellular Therapeutics has announced the appointment of Andrew Gengos as president and chief executive and member of the Board of directors.
With more than 20 years in the life science industry, Gengos’ experience includes executive leadership positions in both large and emerging companies, with broad expertise in corporate strategy, business development and transactions, including mergers and acquisitions, financing, operations, commercial planning and healthcare policy.
“ImmunoCellular’s board of directors and management team are confident that Andrew’s integrity, leadership qualities and breadth of experience in directing corporate strategy, forging successful partnerships and establishing alliances with the financial, business, medical and patient communities are exactly the mix of skills and attributes to advance our company to its next stages of maturation and value creation,” said John Yu, ImmunoCellular’s founder and chief scientific officer.
“Joining ImmunoCellular is an extraordinary opportunity to help build a leading biopharmaceutical company with the potential to transform the treatment of cancer,” said Gengos. “I look forward to working with John, the board and the management team to continue to strengthen ImmunoCellular’s relationships with patients and other key stakeholders.”
Gengos was most recently the president and chief executive of Neuraltus Pharmaceuticals, where he led implementation of the company’s clinical, regulatory, fundraising and business development strategies while operating the company on a virtual business model.
Prior to that he served for more than seven years with Amgen where, as vice president, Strategy and Corporate Development, he managed Amgen’s worldwide in-and-outbound business development activities, including a broad slate of acquisitions, licensing, spin-outs, divestitures, corporate venture capital investments, which included board of director positions, and alliance management.
Related Content
Vaccine for brain cancer shows promise
Early stage trials of a new treatment for the brain cancer glioblastoma multiforme have shown …
